Sorry, you're right, I was being imprecise. Obviously, I think (2) is the only viable option here; 23AM doesn't appear to be set up for clinical genomics. But that bias was built into my comment implicitly, not stated directly like it should have been.
I don't think that's accurate either. I think that the FDA views that 23andMe must do one of the following:
1) Provide necessary evidence to support their current marketing claims, or
2) Change the way they are marketing their product, or
3) Cease marketing their product altogether.
I don't see that the FDA necessary has a strong preference as to which manner of complying with the law 23andMe takes.